Suppression of Cell-mediated Immune Reactivity by Peptides Cleaved from Human Fibrinogen

References

• Ambrus J. L., Balian T., Ambrus C. M., Mink I. B., Murphy G. P. Fibrin-fibrinogen degradation products in children with renal disease. N.Y. State J. Med 1974; 74: 1396–1402
   PubMedGoogle Scholar
• Asherson G. L., Ptak W. Contact skin hypersensitivity in the mouse. I. Active sensitization and passive transfer. Immunology 1968; 15: 405–416
   PubMed Web of Science ®Google Scholar
• Badger A. M., Buehler R. J., Cooperband S. R. Immunosuppressive activity and tissue polypeptide antigen content of human ascitic fluids. Cancer Res 1978; 38: 3365–3370
   PubMedGoogle Scholar
• Belew M., Gerdin B., Lindeberg G., Porath J., Saldeen T., Wallin R. Structure-activity relationships of vasoactive peptides derived form fibrin or fibrinogen degraded by plasmin. Biochem. Biophys. Acta 1980; 621: 169–178
   PubMedGoogle Scholar
• Belew M., Gerdin B., Porath J, Saldeen T. Isolation of vasoactive peptides from human fibrin and fibrinogen degraded by plasmin. Thrombos. Res 1978; 13: 983–994
   PubMed Web of Science ®Google Scholar
• Bissenden J. G., Lind N. R., Mackintosh P. Suppression of mixed lymphocyte reactions by pregnancy serum. Clin. Immunol 1980; 39: 195–202
   Google Scholar
• Buluk K., Malofiejew M. The pharmacological properties of fibrinogen degradation products. Br. J. Pharmac 1969; 35: 76–89
   Google Scholar
• Buxzko W. Effect of fibrinogen degradation products on the rat blood vessels. Acta Physiol. Pol 1977; 28: 153–159
   PubMedGoogle Scholar
• Carlsson S. Fibrinogen degradation products in serum from patients with cancer. Acta Chir, Scand 1973; 139: 499–502
   PubMedGoogle Scholar
• Claes G., Svalander C. Studies on platelets and fibrin during rejection of canine renal allografts. Scand. J. Urol. Neprol 1972, Suppl 10
   PubMedGoogle Scholar
• Colvin R. B., Dvorak H. F. Role of the clotting system in cell-mediated hypersensitivity. II. Kinetics of fibrinogen/fibrin accumulation and vascular permeability changes in tuberculin and cutaneous basophil hypersensitivity reaction. J. Immunol 1975; 114: 377–387
   PubMedGoogle Scholar
• Dobbelstein H. Immunmechanismen bei Urämie. Klin. Wschr 1975; 53: 463–466
   Google Scholar
• Edgington T. S., Curtis L. K., Plow E. G. The immunosuppressive activity of plasmic degradation products of human fibrinogen. Thrombos. haemostas 1977; 38: 170
   Google Scholar
• Gerdin B., Saldeen T. Effect of fibrin degradation products on microvascular permeability. Thrombos. Res 1978; 13: 995–1006
   PubMed Web of Science ®Google Scholar
• Gerdin B., Saldeen T., Roszkowski W., Szmigielski S., Stachurska J., Kopéc M. Immunosuppressive effect of vasoactive peptides derived from human fibrinogen. Thrombos. Res 1980; 18: 461–468
   PubMedGoogle Scholar
• Girman G., Pees H., Schwarze G., Scheurlen P. G. Immunosuppression by micromolecular fibrinogen degradation products in cancer. Nature 1976; 259: 399–401
   PubMedGoogle Scholar
• Glasgow A. H., Nimberg R. B., Saporoschetz Menzoian J.O.L., Cooperband S. R. Association of anergy with an immunosuppressive peptide fraction in the serum of patients with cancer. New Engl. J. Med 1974; 291: 1263–1267
   PubMed Web of Science ®Google Scholar
• Harvey H. A., Albright C., Lipton A. The effect of fibrinogen degradation products on in vitro lymphocyte function. Thrombos. Haemostas 1977; 38: 226
   Google Scholar
• Hedner U., Nilsson I. M. Clinical experience with determination of fibrinogen degradation products. Acta Med. Scand 1971; 189: 471–477
   PubMedGoogle Scholar
• Izumi T., Nagai S., Suginoshita T. Serum immunosuppression as a new tool for immunodiagnosis of lung cancer. Cancer Res 1980; 40: 444–447
   PubMedGoogle Scholar
• Krzystyniak K., Stachurska J., Ryzewski J., Bykowska K., Kopeć M. Suppressive effect of low molecular weight fibrinogen degradation products on human and rat lymphocytes. Thrombos. Res 1978; 12: 523–530
   PubMedGoogle Scholar
• Marder V. J., Budzynzki A. Z. Data for defining fibrinogen and degradation products. Thrombos. Diathes. Haemorh 1975; 33: 199, 207
   PubMedGoogle Scholar
• Pritchard H., Micklem H. S. Immune responses in congenitally thymus-less mice. I. Absence of response to oxazolone. Clin. Exp. Immunol 1972; 10: 151–161
   PubMedGoogle Scholar
• Rasche H., Dietrich M. Hemostatic abnormalities associatid with malignant diseases. Eur. J. Cancer 1977; 13: 1053–1064
   Google Scholar
• Richardson D. L., Pepper D. S., Kay A. B. Chemotoxis for human monocytes by fibrinogen-derived peptides. Brit. J. Haemat 1976; 32: 507–513
   PubMed Web of Science ®Google Scholar
• Riggio R. R., Schwartz G. H., Bull F. G., Stenzel K. H., Rubin A. L. α2-globulins in renal graft rejection. Effects on in vitro lymphocyte function. Transplantation 1969; 8: 689–694
   PubMedGoogle Scholar
• Roszkowski W., Stachurska J., Gerdin B., Saldeen T., Kopeć M. Peptides cleaved from fibrinogen by plasmin enhance the progression of L-1 Sarcoma in BALB/c Mice. Eur. J. Cancer Clin. Oncol 1981; 17: 889–892
   PubMedGoogle Scholar
• Scheurlen P. G., Baaka M., Frey N., Moers P., Sieberth G. Über Immunoinsuffizienz bei chronischen uremischen Nierenkrankungen. Dtsch Med. Wschr 1969; 94: 17–20
   PubMedGoogle Scholar
• Stachurska J., Lopaciuk S., Gerdin B., Saldeen T., Korościk A., Kopeć M. Effects of proteolytic degradation products of human fibrinogen and of human Factor VIII on platelet aggregation and vascular permeability. Thrombos. Res 1979; 15: 663–672
   PubMedGoogle Scholar
• Takagi T., Doolittle R. F. Amino acid sequence studies on the α-chain of human fibrinogen. Biochemistry 1975; 14: 5149–5145
   PubMedGoogle Scholar
• Triantaphyllopoulos E., Triantaphyllopoulos D. C. Fibrinolysis: the micromolecular derivatives. Brit. J. Haemat 1968; 15: 337–343
   PubMed Web of Science ®Google Scholar
• Zacharski L. R., Henderson W. G., Richles F. R., Forman Cornell W.B.C.J., Jr., et al. Rational and experimental design for the VA Cooperative Study of Anticoagulation (Warfarin) in the Treatment of Cancer. Cancer 1979; 44: 632–741
   Google Scholar